Associations of inflammatory and hemostatic variables with the risk of recurrent stroke by Woodward, M. et al.
 
 
 
 
 
 
 
Woodward, M., Lowe, G.D.O., Campbell, D.J., Colman, S., Rumley, A., 
Chalmers, J., Neal, B.C., Patel, A., Jenkins, A.J., Kemp, B.E. and 
MacMahon, S.W. (2005) Associations of inflammatory and hemostatic 
variables with the risk of recurrent stroke.Stroke, 36 (10). pp. 2143-2147. 
ISSN 0039-2499 
 
http://eprints.gla.ac.uk/19688/ 
 
Deposited on: 23 January 2012 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
Kemp and Stephen W. MacMahon
Rumley, John Chalmers, Bruce C. Neal, Anushka Patel, Alicia J. Jenkins, Bruce E. 
Mark Woodward, Gordon D.O. Lowe, Duncan J. Campbell, Sam Colman, Ann
Recurrent Stroke
Associations of Inflammatory and Hemostatic Variables With the Risk of
ISSN: 1524-4628 
Copyright © 2005 American Heart Association. All rights reserved. Print ISSN: 0039-2499. Online
Stroke is published by the American Heart Association. 7272 Greenville Avenue, Dallas, TX 72514
doi: 10.1161/01.STR.0000181754.38408.4c
2005, 36:2143-2147: originally published online September 8, 2005Stroke 
 http://stroke.ahajournals.org/content/36/10/2143
located on the World Wide Web at: 
The online version of this article, along with updated information and services, is
 http://www.lww.com/reprints
Reprints: Information about reprints can be found online at 
  
 journalpermissions@lww.com
410-528-8550. E-mail: 
Fax:Kluwer Health, 351 West Camden Street, Baltimore, MD 21202-2436. Phone: 410-528-4050. 
Permissions: Permissions & Rights Desk, Lippincott Williams & Wilkins, a division of Wolters
  
 http://stroke.ahajournals.org//subscriptions/
Subscriptions: Information about subscribing to Stroke is online at 
 at GLASGOW UNIV LIB on January 23, 2012http://stroke.ahajournals.org/Downloaded from 
Associations of Inflammatory and Hemostatic Variables
With the Risk of Recurrent Stroke
Mark Woodward, PhD; Gordon D.O. Lowe, MD; Duncan J. Campbell, MD, PhD; Sam Colman;
Ann Rumley, PhD; John Chalmers, MD, PhD; Bruce C. Neal, PhD; Anushka Patel, MD;
Alicia J. Jenkins, MD, PhD; Bruce E. Kemp, PhD; Stephen W. MacMahon, PhD
Background and Purpose—Several prospective studies have shown significant associations between plasma fibrinogen,
viscosity, C-reactive protein (CRP), fibrin D-dimer, or tissue plasminogen activator (tPA) antigen and the risk of primary
cardiovascular events. Little has been published on the associations of these variables with recurrent stroke. We studied
such associations in a nested case-control study derived from the Perindopril Protection Against Recurrent Stroke Study
(PROGRESS).
Methods—Nested case-control study of ischemic (n472) and hemorrhagic (n83) strokes occurring during a
randomized, placebo-controlled multicenter trial of perindopril-based therapy in 6105 patients with a history of stroke
or transient ischemic attack. Controls were matched for age, treatment group, sex, region, and most recent qualifying
event at entry to the parent trial.
Results—Fibrinogen and CRP were associated with an increased risk of recurrent ischemic stroke after accounting for the
matching variables and adjusting for systolic blood pressure, smoking, peripheral vascular disease, and statin and
antiplatelet therapy. The odds ratio for the last compared with the first third of fibrinogen was 1.34 (95% CI, 1.01 to
1.78) and for CRP was 1.39 (95% CI, 1.05 to 1.85). After additional adjustment for each other, these 2 odds ratios stayed
virtually unchanged. Plasma viscosity, tPA, and D-dimer showed no relationship with recurrent ischemic stroke,
although tPA was significant for lacunar and large artery subtypes. Although each of these variables showed a negative
relationship with recurrent hemorrhagic stroke, none of these relationships achieved statistical significance.
Conclusions—Fibrinogen and CRP are risk predictors for ischemic but not hemorrhagic stroke, independent of potential
confounders. (Stroke. 2005;36:2143-2147.)
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There is increasing evidence that hemostatic and in-flammatory variables are associated with cardiovascu-
lar events in prospective studies, including coronary heart
disease (CHD) and stroke.1 Most data are available for
fibrinogen, which may play a causal role in atherothrom-
botic events through effects on atherogenesis, thrombogen-
esis, or ischemia distal to atherothrombotic stenoses or
occlusions.1– 4 Several prospective studies have reported
that fibrinogen is associated with risk of stroke,5–9 al-
though not the Caerphilly and Speedwell studies.10 Plasma
fibrinogen is an important determinant of plasma and
blood viscosity, which have also been reported to be
associated with the risk of CHD,11–15 although reports for
stroke have been conflicting.10,13 In part, the possible
association between viscosity and stroke may be mediated
by an association between viscosity and elevated carotid
intima-media thickness, at least in men.16 Ernst et al17
observed that fibrinogen, plasma viscosity, blood viscos-
ity, and cholesterol were associated with risk of recurrence
over 2 years in 523 survivors of first stroke. Similar
findings have been reported for recurrent myocardial
infarction.18
There are fewer published data on the association of
other hemostatic or inflammatory variables with risk of
CHD and stroke.1 Recent meta-analyses have shown that
C-reactive protein (CRP),3,19 von Willebrand factor
(vWF),19,20 fibrin D-dimer,21 and tissue plasminogen acti-
vator (tPA) antigen,22 but not plasminogen activator inhib-
itor type 1,22 are associated with risk of CHD events
in samples of general populations. There are limited
published data for the associations of CRP,23,24 vWF
(or its complexed coagulation factor, factor VIII),8,9,23,24
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D-dimer7–9,25 or tPA antigen8,9,25–27 with risk of stroke in
prospective studies.
In PROGRESS,28,29 baseline plasma samples were cen-
trally stored for analysis, in nested case-control studies, of
emerging potential risk factors for recurrent stroke, including
hemostatic and inflammatory variables.28 Here, we report the
associations of plasma fibrinogen, viscosity, CRP, D-dimer,
and tPA antigen with recurrent strokes (ischemic and
hemorrhagic).
Materials and Methods
The design28 and principal results29 of PROGRESS have been
published previously. Briefly, 6105 patients with a history of stroke
or transient ischemic attack (TIA) were recruited and each patient
randomly assigned active treatment (n3051) or placebo (n3054).
For those deemed suitable by the responsible physician, dual therapy
was allocated: perindopril with indapamide or double placebo.
Others received monotherapy: perindopril or single placebo. Patients
were followed for a mean of 3.9 years, during which time stroke
(fatal or nonfatal) occurred in 307 (10%) in the active treatment
group and 420 (14%) in the placebo group (relative risk reduction,
28%; 95% CI, 17 to 38; P0.0001).29
At baseline, venous blood samples collected from 5918 (97%) of
patients were anticoagulated with K2 EDTA and centrifuged at
2000g for 10 min at 4°C. Aliquots (1.5 mL) of plasma were stored
at 80°C for an average of 6 years. Plasma fibrinogen was assayed
by immunonephelometry (Dade-Behring).30 Plasma viscosity was
measured in a semiautomated capillary viscometer (Coulter) and
expressed at 37°C with a correction for storage of frozen samples.31
Fibrin D-dimer and tPA antigens were measured by ELISAs
(Biopool) as described previously.21,22 CRP was measured by high-
sensitivity nephelometry (Dade Behring). Laboratory personnel were
“blinded” to the case-control status of samples. The interassay
coefficients of variation for control samples were: fibrinogen 5.3%;
viscosity 0.9%; tPA 6.5%; D-dimer 5.3%; and CRP 3.9%.
The base population for this study was all those who had plasma
frozen and stored within 48 hours of venipuncture and whose most
recent qualifying event (stroke or TIA) at baseline in the clinical trial
occurred 1 month ago. These restrictions give protection against
deterioration of the blood samples and confounding attributable to
acute-phase reactant increases in blood variables as a result of the
incident stroke or its acute complications.
Stroke cases comprised anyone with a stroke recorded during
follow-up. Using standard methodology for nested case-control
studies,32 each case was randomly matched to between 1 and 3
controls selected from all those free of recurrent stroke at the time of
recurrent stroke for that case. Under this sampling scheme, any case
may be selected as a control for other cases for whom recurrent
stroke predates their own, whereas cases may have common controls.
The overall sample size was restricted so that the total number of
people selected who had no stroke during follow-up outnumbered the
cases in the ratio of 1 to 2. Matching variables were age (within 5
years), sex, treatment allocated (active/placebo), therapy (mono/
dual), region (Australia or New Zealand/China/Japan/France or
Belgium/Italy/Sweden/UK or Ireland) and most recent qualifying
event (ischemic stroke or TIA/hemorrhagic stroke/stroke of un-
known type) at the trial baseline. Prespecified ischemic and hemor-
rhagic stroke substudies isolated those cases and their matched
controls, who had ischemic or hemorrhagic strokes as their first
recorded stroke event.
Odds ratios were calculated according to equal thirds of the
distribution of each risk factor in the total sample (cases and controls
together) using conditional logistic regression models.32 As well as
unadjusted analyses (allowing only for the confounding effects of the
matched variables, by design), additional adjustments through the
regression model were made for systolic blood pressure, smoking
(current/non), peripheral artery disease, statin therapy, and antiplate-
let therapy. Because fibrinogen and CRP are acute-phase proteins,
each was additionally adjusted for the other.
Results
The nested case-control study included 1773 patients: 591
were cases (83 hemorrhagic strokes, 472 ischemic strokes,
and 36 of unknown type), and 1182 were controls who did not
subsequently become cases. Controls satisfying all matching
criteria were found for 572 of these cases; 19 were incom-
pletely matched. After the addition of cases who acted as
matched controls for other cases and taking account of
controls who acted for 1 case, there were 33 cases with 1,
213 with 2, and 345 with 3 matched controls. Altogether, 89
cases served as controls for 1 other case.
Table 1 shows, according to type of stroke, summaries of
the demographic randomization group and risk factor data
according to whether the subject became a case or not during
PROGRESS. In this presentation, unique cases and controls
are shown, that is, after removing duplicates consequent to
the unbiased nested design. In the ischemic stroke study,
fibrinogen and CRP were significantly (P0.05) higher in
cases than controls, as was systolic blood pressure and the
prevalence of diabetes, smoking, peripheral artery disease,
atrial fibrillation, and left ventricular hypertrophy. In the
hemorrhagic stroke study, there were no significant differ-
ences, although this could be explained by the lack of power.
Table 2 shows the odds ratios for hemorrhagic, ischemic,
and total stroke associated with thirds of the hemostatic and
inflammatory variables. Also included is a test for trend
across the thirds. None of the variables showed any signifi-
cant relationship with hemorrhagic stroke. Only fibrinogen
and CRP showed significant associations with ischemic
stroke: the odds ratio (95% CI) comparing the last to the first
third was 1.43 (1.08 to 1.89) for fibrinogen and 1.52 (1.15 to
2.00) for CRP. Adjustment for systolic blood pressure and
smoking, in addition to the matching variables adjusted by
design, attenuated the odds ratios by 2% to 10%. A noticeable
difference between the 2 sets of results is the negative
relationships for hemorrhagic stroke and the positive relation-
ships for ischemic stroke for all variables. As a consequence,
and because ischemic strokes outnumbered hemorrhagic by
almost 6:1, results for total stroke were an attenuated version
of those for ischemic stroke. Only fibrinogen had a significant
relationship.
To investigate subtypes of ischemic stroke, we analyzed 66
cases of large artery infarct and 114 cases of lacunar infarct,
and their matched controls, separately. The only other sub-
type identified in PROGRESS was cardioembolic, which had
too few cases with blood samples (29) to justify analyses.
Allowing for the much wider CIs, results were generally
similar to those for all ischemic strokes. Thus, the odds ratio
(95% CI) for large artery infarct for the adjusted analysis of
Table 2, comparing the top to bottom thirds, was 1.34 (0.59
to 3.04) for fibrinogen and 1.48 (0.64 to 3.43) for CRP.
Corresponding results for lacunar infarct were 1.82 (0.99 to
3.13) and 1.86 (1.00 to 3.43). Now there was, however,
evidence of a positive effect for tPA, in contrast to the overall
result. The corresponding results to those above were 1.78
(0.81 to 3.91) and 1.98 (1.10 to 3.60), with P values for trend
of 0.07 and 0.02, respectively.
The correlation between fibrinogen and CRP was 0.49 in
cases and controls. There was no interaction between them
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for any of the 3 outcomes (P0.14). Extra adjustment of
fibrinogen for CRP, or fibrinogen for CRP, made no differ-
ence, to 1 decimal place, to either of the adjusted odds ratios
comparing the extreme thirds for ischemic stroke.
Discussion
This is the largest reported single prospective study to date of
the associations between plasma fibrinogen, viscosity, CRP,
fibrin D-dimer, tPA antigen, and the risk of recurrent
stroke.3,15,19–22 The main finding is that plasma fibrinogen is
a significant, independent risk factor for recurrent stroke.
This agrees with a previous study in stroke survivors,17 which
observed a significantly higher baseline fibrinogen level for
those with recurrent stroke (n67) compared with those who
did not experience recurrence (n456), and also with a
meta-analysis of 3 other prospective studies of patients with
TIA or minor stroke (total recurrent ischemic strokes
n512).33 Our study also clarifies that the association of
fibrinogen with recurrent stroke applies only to ischemic
stroke, as also observed in the meta-analysis.33 Indeed, the
odds ratio for hemorrhagic stroke was lowest in the highest
third of fibrinogen. The association between fibrinogen and
first stroke is currently being studied in the Fibrinogen
Studies Collaboration.34
Potential confounders of the association between fibrino-
gen and ischemic stroke include blood pressure, smoking
habit, and the acute-phase reactant behavior of plasma fibrin-
ogen.1–4 However, when we additionally adjusted for CRP
(the generally accepted best measure of inflammatory reac-
tions in cardiovascular disease19), estimates of the effect of
fibrinogen were little changed for recurrent ischemic stroke.
There are several plausible biological pathways through
which increasing plasma fibrinogen levels might increase the
risk (and outcome) of stroke, including atherogenesis, throm-
bogenesis, and (through its rheological effects) promoting
cerebral ischemia distal to atherothrombotic stenoses or
occlusions.1–4,13,16,17,35,36 Our results for CRP are consistent
with previous studies that reported associations between CRP
and risk of a first stroke.23,24
In contrast to previous studies of first13 or recurrent17
stroke, we did not observe a significant association between
plasma viscosity and recurrent stroke in the present study; nor
did an analysis of first stroke in the Caerphilly and Speedwell
studies.10 A recent meta-analysis of prospective studies ob-
TABLE 1. Baseline Summary Data for All Subjects in the Nested Case-Control Study Classified by Whether or Not They
Developed Either of the Major Subtypes of Stroke During PROGRESS
Variable
Hemorrhagic Stroke Study Ischemic Stroke Study
Cases
(n83)
Controls
(n199)* P Value
Cases
(n472)
Controls
(n1011)* P Value
Mean (95% CI)
SBP, mm Hg 149.7 (145.4–154.0) 145.9 (143.4–148.4) 0.11 149.9 (148.1–151.6) 147.4 (146.3–148.6) 0.02
DBP, mm Hg 88.4 (85.9–91.0) 85.9 (84.5–87.2) 0.08 86.0 (85.1–87.0) 85.0 (84.4–85.7) 0.10
Age, y† 62.5 (60.6–64.5) 62.4 (61.2–63.6) 0.92 66.5 (65.7–67.3) 66.2 (65.7–66.7) 0.48
BMI, kg/m2 24.9 (24.1–25.7) 25.3 (24.8–25.8) 0.42 25.8 (25.5–26.2) 25.5 (25.3–25.7) 0.13
Fibrinogen, g/L 3.58 (3.40–3.76) 3.76 (3.63–3.89) 0.11 3.87 (3.79–3.96) 3.73 (3.70–3.78) 0.005
Viscosity, mPa.s 1.28 (1.26–1.30) 1.30 (1.29–1.31) 0.06 1.29 (1.28–1.30) 1.29 (1.28–1.29) 0.54
tPA, ng/mL 8.61 (7.53–9.69) 9.08 (8.41–9.76) 0.45 9.44 (8.98–9.89) 9.00 (8.72–9.28) 0.11
D-dimer, ng/mL 118.4 (72.2–164.6) 161.0 (109.1–212.8) 0.23 198.7 (160.1–237.4) 183.0 (157.7–208.3) 0.50
CRP, mg/L‡ 1.47 (1.10–1.96) 1.62 (1.35–1.94) 0.57 2.20 (1.98–2.45) 1.91 (1.77–2.05) 0.03
No. (%)
Males† 63 (76) 154 (77) 0.88 348 (74) 750 (74) 0.85
Diabetes 6 (7) 19 (10) 0.65 85 (18) 113 (11) 0.0004
Smokers 15 (18) 43 (22) 0.63 110 (23) 173 (17) 0.006
Active treatment† 22 (27) 52 (26) 1.00 208 (44) 462 (46) 0.58
Dual therapy† 45 (54) 110 (55) 0.90 265 (56) 569 (56) 1.00
Previous heart disease 11 (13) 39 (20) 0.23 91 (19) 172 (17) 0.31
Peripheral artery disease 1 (1) 7 (4) 0.94 32 (7) 39 (4) 0.02
Treated hypertension 49 (59) 117 (59) 1.00 250 (53) 483 (48) 0.07
Atrial fibrillation 7 (8) 12 (6) 0.45 54 (11) 75 (7) 0.01
Valvular heart disease 2 (2) 1 (1) 0.21 14 (3) 24 (2) 0.49
Left ventricular hypertrophy 13 (16) 17 (9) 0.09 41 (9) 59 (6) 0.05
Statin therapy 5 (6) 13 (7) 1.00 36 (8) 77 (8) 1.00
Antiplatelet therapy 39 (47) 104 (52) 0.44 362 (77) 780 (77) 0.84
SBP indicates systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index.
*Controls who did not go on to become cases during PROGRESS; †matching variables; ‡analyzed on the logarithmic scale; estimates shown after
back-transformation.
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served that circulating levels of tPA antigen were indepen-
dently associated with risk of CHD.22 There is little published
information on the association of tPA antigen with risk of
stroke.8,9,26,27 In the present study, we observed an association
of tPA antigen with risk of lacunar and large artery infarcts,
but not ischemic or total stroke. Another meta-analysis
observed that circulating levels of fibrin D-dimer (a marker of
activation of blood coagulation and fibrinolysis) were also
independently associated with risk of CHD.21 Again, there is
little published information on the association of D-dimer
with risk of stroke.7–9,25 In the present study, we observed no
significant association of D-dimer with risk of recurrent
stroke. Two prospective studies37,38 have reported significant
associations of D-dimer with risk of stroke in patients with
atrial fibrillation. Only 11% of patients with ischemic stroke
had atrial fibrillation in this study (Table 1).
This study adds to the evidence that plasma fibrinogen and
CRP are predictors of risk for (recurrent) ischemic stroke.
Meta-analyses are required to determine the additive value of
plasma fibrinogen and CRP to classical risk factors in the
prediction of first and recurrent stroke and to determine
whether or not chronic reduction in fibrinogen or CRP
reduces the risk of stroke.
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